NCT05213221View on ClinicalTrials.gov

Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

September 1, 2022

Study Completion Date

June 1, 2023

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

Envafolimab

300mg, subcutaneous injection, q3w

PROCEDURE

TACE

The first TACE will be started on d1, and the subsequent TACE will be performed on demand.

DRUG

Lenvatinib

8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)

Trial Locations (1)

310003

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER